Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19, Zacks reports.
Abeona Therapeutics Trading Down 0.6 %
Shares of NASDAQ ABEO traded down $0.03 during midday trading on Monday, reaching $5.12. The company had a trading volume of 455,643 shares, compared to its average volume of 402,180. The stock has a market cap of $222.57 million, a PE ratio of -1.90 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The firm's fifty day moving average price is $5.43 and its 200-day moving average price is $5.83. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on ABEO shares. Oppenheimer started coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday. Finally, StockNews.com downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.50.
Get Our Latest Analysis on ABEO
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Articles
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
